文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

ARDS的成本:一项系统综述

The Cost of ARDS: A Systematic Review.
PubMed 文献 · Chest · 2021-08-31
一句话结论ARDS住院成本从8,476至547,974美元(2021年美元)不等,高成本见于低质量研究、美国医疗体系及创伤队列。

该研究系统检索截至2021年4月29日的文献,纳入报告成人ARDS患者成本数据的原创研究,共22篇(49,483例患者)适合数据提取。住院平均成本范围为8,476至547,974美元(2021年美元),在美国医疗体系、低质量研究及创伤队列中最高;门诊成本在再入院率高、随访时间长及美国医疗体系中最高。成本数据异质性大,综合合成有助于在具体背景下解释成本估计。

要点

  • 成人ARDS住院平均成本范围8,476至547,974美元(2021年美元),跨度极大。
  • 住院成本在低质量研究、美国医疗体系及创伤队列中最高。
  • 门诊成本在再入院率高、随访时间长及美国医疗体系中最高。
  • 系统综述纳入22篇文献共49,483例成人ARDS患者,数据来自多种医疗体系和经济视角。
  • 成本估计需结合具体医疗体系、经济视角和 costing 方法解读,不可直接通用。

适用人群与场景

  • 成人ICU中ARDS患者(纳入标准:原始出版物报告成人ARDS患者成本数据)

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 系统综述,检索MEDLINE、Embase、Central、EconLit至2021年4月29日,最终纳入22篇出版物(49,483例患者)提取成本数据。
  • 住院平均成本范围为8,476至547,974美元(2021年美元),在美国医疗体系、低质量研究及创伤队列中最高。
  • 门诊成本在再入院率高、随访时间长及美国医疗体系中最高。
  • 出版物涵盖多种医疗体系、经济视角、成本核算方法和时间范围。

证据类型、等级与局限

  • 证据类型:系统综述(PROSPERO注册号CRD42020192487),使用改良版Quality of Health Economic Studies Instrument评估发表质量。
  • 局限:成本数据异质性大,受医疗体系、经济视角、核算方法及研究质量影响;低成本研究质量较高,高成本研究质量较低。

对床旁实践的改变

  • 急诊/ICU医生在引用ARDS成本数据时需注意其来源于特定医疗体系、经济视角和核算方法,不能直接外推至本机构。
  • 美国医疗体系及创伤相关ARDS队列的成本估计较高,资源规划时应考虑本地体系差异。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: ARDS is an inflammatory condition of the lungs and is a common condition in adult ICUs. The resources required and costs of care for patients with ARDS are significant because of the severity of the illness and extended ICU lengths of stay.

RESEARCH QUESTION: What are the costs associated with ARDS?

STUDY DESIGN AND METHODS: We systematically searched the literature through April 29, 2021, for articles relevant to ARDS and costs. MEDLINE, Embase, Central, and EconLit databases were searched, and articles that reported on cost data from an original publication in adult patients with ARDS were included. Two authors independently assessed articles for inclusion and extracted data elements related to costs, methodology, health care system type, economic perspective, and clinical data. Publication quality was assessed using a modified version of the Quality of Health Economic Studies Instrument.

RESULTS: Four thousand six hundred sixty-three publications were found, of which 110 were included for full-text review (κ = 0.72). A total of 22 publications (49,483 patients) were suitable for data extraction. The publications represented a broad range of health care systems, economic perspectives, costing methodology, and time frames. Mean inpatient costs ranged from $8,476 (2021 US dollars [USD]) to $547,974 (2021 USD) and were highest in publications of lower quality and in American health systems and were associated with trauma cohorts. Outpatient costs were highest in publications with higher readmission rates, longer durations of follow-up, and in American health systems.

INTERPRETATION: A wide range of costing data is available for ARDS. A comprehensive synthesis of this literature frames the reasons for this and allows estimates to reflect the context in which they were assessed. This information will be of value to researchers and administrators interested in the economics of caring for patients with ARDS.

TRIAL REGISTRY: PROSPERO; No.: CRD42020192487 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192487.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Boucher PE, Taplin J, Clement F, et al. The Cost of ARDS: A Systematic Review. Chest. 2021. PMID: 34478719. doi:10.1016/j.chest.2021.08.057

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。